LAURA: Improved trend for OS benefit with osimertinib versus placebo in patients with unresectable stage III EGFR-mutant NSCLC
Lung, Respiratory and Thoracic Cancer
ELCC 2025
Related content
Lung, Respiratory and Thoracic Cancer
Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy
Eur J Cancer
Arriola E, Casarini I, Özgüroğlu M, Huang M, Takahashi T, Lai X, Goto K, Maneenil K, Lee KH, Cobo M, Valdiviezo N, Evans A, Bolanos A, Huang X, Lai R, Ramalingam SS
doi: 10.1016/j.ejca.2026.116744
Lung, Respiratory and Thoracic Cancer
Upfront osimertinib and as sequential therapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort-the smile study
Transl Lung Cancer Res
Auclin E, Du Rusquec P, Albarran-Artahona V, Aboubakar F, Gerber H, Epaillard N, Recondo G, De Giglio A, Berthou H, Laguna JC, Gorria T, Blaquier JB, Jimenez-Munarriz B, Tagliamento M, Di Federico A, Sacco G, Minatta J, Girard N, Moran-Bueno T, Lopez-Castro R, Besse B, Mezquita L
doi: 10.21037/tlcr-24-881
SPECIAL REPORT
Lung, Respiratory and Thoracic Cancer
MARIPOSA Study: Frontline amivantamab plus lazertinib reduces acquired resistance versus osimertinib in patients with NSCLC harboring common EGFR mutations*
WCLC 2025
Lung, Respiratory and Thoracic Cancer
FLAURA2: Frontline osimertinib plus chemotherapy significantly improves OS in EGFR-mutated advanced NSCLC
WCLC 2025
Lung, Respiratory and Thoracic Cancer
CheckMate 816: Neoadjuvant nivolumab plus chemotherapy provides long-term OS benefit in patients with early-stage NSCLC
Lung, Respiratory and Thoracic Cancer
Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study
Lung Cancer
Ahn MJ, Lin SH, Yang CT, Lee JB, Neal JW, Okishio K, Nishino K, Smith D, Rauter M, Jimenez M, Nasirova F, Kim Y
doi: 10.1016/j.lungcan.2025.108748
Lung, Respiratory and Thoracic Cancer
Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis
Lung Cancer
Hayashi H, Cho BC, Kim YJ, Lee SH, Danchaivijitr P, Alip A, Xiong H, How SH, Chang GC, Yang JC, Yamanaka Y, Nahit Şendur MA, Prabhash K, Azuma K, Akawung A, Fennema E, Tang X, Shah S, Sethi S, Lu S
doi: 10.1016/j.lungcan.2026.109305
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
Adv Ther
Girard N, Macouillard P, Byng D, Meng J, Coerts F, Hunter S, Struebing A, Xiong Y, Park S, Haq MI, Tymejczyk O, Chouaid C, Audigier-Valette C, Debieuvre D, Quantin X, Bosquet L, Pérol M
doi: 10.1007/s12325-025-03465-4
Lung, Respiratory and Thoracic Cancer
Lazertinib Versus Osimertinib in Previously Untreated EGFR-mutant Advanced NSCLC: A Randomized, Double-blind, Exploratory Analysis From MARIPOSA
J Thorac Oncol
Lee SH, Lu S, Hayashi H, Felip E, Spira AI, Girard N, Kim YJ, Ostapenko Y, Danchaivijitr P, Liu B, Alip A, Korbenfeld E, Mourão Dias J, Lee KH, Xiong H, How SH, Cheng Y, Chang GC, Yang JC, Besse B, Thomas M, Shah S, Baig M, Curtin JC, Zhang J, Xie J, Sun T, Sethi S, Wang M, Fennema E, Daksh M, Ennis M, Bauml JM, Cho BC
doi: 10.1016/j.jtho.2025.06.030